Aspen Neuroscience, Inc. ASPE
Aspen Neuroscience, Inc. (Nasdaq: ASPE) is a CNS/neurology/psychiatry drug developer. Its lead program, sasineprocel, is in Phase 2 for Parkinson's disease (PD). Its next catalyst on record is sasineprocel: Initiate biopsy collection for Phase 3 trial (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: sasineprocel — Initiate biopsy collection for Phase 3 trial (2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| sasineprocel | Parkinson's disease (PD) - sporadic | cell therapy | Phase 2 |
| sasineprocel | Parkinson's disease (PD) - genetic | cell therapy | Phase 1 |
| Microglia program | Pediatric leukodystrophies | gene therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.